Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

The Genetic Basis for Vulnerability to Substance Abuse

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2005 by National Institute on Drug Abuse (NIDA).
Recruitment status was:  Recruiting
Information provided by:
National Institute on Drug Abuse (NIDA) Identifier:
First received: October 31, 2005
Last updated: NA
Last verified: October 2005
History: No changes posted
This investigation seeks to better define the genetic basis for vulnerability to substance abuse.

Condition Intervention
Substance Abuse
Procedure: Blood draw

Study Type: Observational
Study Design: Observational Model: Case Control
Observational Model: Natural History
Time Perspective: Cross-Sectional
Time Perspective: Prospective
Official Title: Allelic Linkage in Substance Abuse

Further study details as provided by National Institute on Drug Abuse (NIDA):

Estimated Enrollment: 8000
Study Start Date: August 1992
Estimated Study Completion Date: February 2006
Detailed Description:

Dopamine (DA), a neurotransmitter helping to mediate reward and reinforcement, has been putatively linked to the development of substance abuse, alcohol abuse, and alcoholism. Identification of specific vulnerability-association alleles for receptors, other molecules within the reward mediating system, and other genes that may predispose individuals to the development of such disorders is the goal of the study.

This investigation will help elucidate the genetic underpinnings of substance abuse, potentially leading to the improved methods to diagnose those at risk and to help develop better therapeutic interventions.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Substance abusers
  • Allow for blood draw

Exclusion Criteria:

  • Cognitively impaired
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00247819

United States, Maryland
National Institute on Drug Abuse
Baltimore, Maryland, United States, 21224
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Principal Investigator: George Uhl, M.D., Ph.D. National Institute on Drug Abuse (NIDA)
  More Information

Gelernter J, Moises H, Grandy D, et al. Exclusion of schizophrenia triat from regions of the D2 dopamine receptor and prophobilinogen deaminase genes. In: 28th Annual Meeting, American College of Neurophyschopharmacology, December 13, 1980; Maui, Hawaii, Abstracts p.216.
Wyatt RJ, Farouk K, Suddath R, Hitri A. The role of dopamine in cocaine use and abuse. Psychiatric Annals 1988; 18:531-534. Identifier: NCT00247819     History of Changes
Other Study ID Numbers: NIDA-IRP-148 
Study First Received: October 31, 2005
Last Updated: October 31, 2005
Health Authority: United States: Federal Government

Keywords provided by National Institute on Drug Abuse (NIDA):
Substance abuse

Additional relevant MeSH terms:
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders processed this record on December 09, 2016